Measles (Rubeola) in Infants

Measles or rubeola is a powerfully contagious acute disease triggered by an RNA virus of the genus Morbillivirus of the family Paramyxoviridae, manifested through fever and a rash. The airborne transmission of measles is primarily achieved through breath droplets that move in short excursions and can also be spread via small aerosol droplets that persist in the atmosphere for a few hours. The incubation period of measles between infection and the onset of the rash is approximately 12.5 days (Moss & Griffin, 2024). Despite the existence of the mumps, measles, and rubella (MMR) vaccine, infants are highly vulnerable to being infected and developing severe effects because of such an age gap and the decreasing maternal antibodies. Measles has been a significant health menace to the population, especially in regions where there are minimal resources and access to health care and vaccinations.

Signs and Symptoms

The first phase of measles symptoms in infants that last between 4-7 days includes cough, Koplik spots, conjunctivitis or coryza, watery and red eyes. The World Health Organization (2024) notes that the rash often develops on the forehead and upper neck 7–18 days after contact. It spreads to the feet and hands three days later and often fades after 5–6 days. Infants are usually irritated, lose their appetite, and dehydrate during feeding. Kondamudi and Waymack (2023) indicate that pneumonia, diarrhea, and encephalitis are more serious and common complications among infants and result in hospitalization or death, estimated to be between 100000 and 200000 yearly.

Pathophysiology

In newborns, measles starts with the virus being drawn in by respiratory droplets and infecting immune cells (dendritic cells and lymphocytes) within the respiratory tract. This subsequently disseminates to many lymphoid tissues, where it replicates, and the virus spreads to the bloodstream, resulting in viremia. Then the virus is expelled in respiratory discharges, and the infected infants become extremely contagious to others. This initial inflammatory stage leads to early cough, runny nose, eye reddening, and fever symptoms (Kondamudi & Waymack, 2023). The resultant rash is due to the immune cells attacking the endothelial cells infected with the virus.

The virus also inhibits the infant’s immune system by interfering with interferon production, which postpones the body’s defense systems. This is followed by antibody responses, whereby IgM is produced and IgG offers long-term immunity. T-helper cells are required to clear the infection through cellular immunity. However, measles will also lead to “immune amnesia,” where the old memory cells are substituted by the new ones, leaving infants at risk of pneumonia, ear infections, and diarrhea (Kondamudi & Waymack, 2023). The most serious case is the relatively rare but life-threatening late complication, Subacute sclerizing panencephalitis (SSPE), which can occur years after the initial infection.

Diagnosis

Infants with measles need a clinical diagnosis in addition to a laboratory diagnosis. The presence of fever, cough, conjunctivitis, and rash is a powerful indication of measles. The spots proposed by Koplik are particular, although not always present. A person can be confirmed to have measles and eliminate unlikely diseases such as rubella or roseola through lab tests. Thirdly, Enzyme Immunoassay (EIA) can be used indirectly to capture measles-specific immunoglobulin M (IgM) antibodies (Filardo et al., 2024). Moreover, real-time RT-PCR can be applied using throat swabs, nasopharyngeal, and urine specimens.

Treatments and Prevention

Measles has no antiviral drug; hence, the treatment of the infant is focused on supportive care. This is by ensuring adequate hydration, fever with antipyretics, and bacterial infections of the second degree with antibiotics in case of necessity. Vitamin A supplement also increases immune neutrality, protect the epithelial mucosa, and reduce mortality rates of malnourished children by 50 or more (National Institutes of Health, 2023). Nevertheless, Vitamin A is only to be used under the supervision of a doctor because an overdose may cause toxicity. In its turn, it may cause lightheadedness, nausea, vomiting, fatigue, and liver failure.

The MMR vaccine, a live attenuated measles virus, is a significant means of prevention. Kondamudi and Waymack (2023) indicate that the initial dose is usually administered at 12-15 months, and the second between 4-5 years. Nevertheless, children below 12 months are still not vaccinated and rely on herd immunity as a source of protection. Infants can receive a premature immunization at six months in regions with high transmission risks, but further complete vaccination is needed (Kondamudi & Waymack, 2023). Isolation of infected persons, measures of domestic infection control, and fortification of community immunization drives are preventive measures.

Epidemiology

Even though measles is considered to be avoidable with the help of a vaccine, it remains one of the main global health issues. Chen et al. (2025) note that over 10 million measles cases, and 707500 deaths were reported in 2023, the majority of them being due to unvaccinated or poorly vaccinated kids aged below five years, had been reported, and Africa remained the most affected area. Countries like the US report few cases because they execute successful measles vaccination campaigns that facilitate outreach and access (Chen et al., 2025). Most cases reported are imported cases connected to international travel, and some communities resist vaccines, thus increasing infant risks.

Prognosis

Access to healthcare, age, and nutrition all determine the prognosis of measles. Children in the developed world are well nourished, so they recover within two to three weeks. Anh and Mulholland (2025) indicate that complications develop in approximately thirty percent of the cases, with pneumonia being the primary cause of death. Children with low immunity or who have been affected by malnutrition are at risk of blindness, deafness, or brain damage. Vaccines and supportive therapy will improve outcomes and reduce mortality.

Conclusion

Measles is still a threat to babies despite its preventability by vaccines. This condition is more susceptible in infants since they are resistant to measles by maternal antibodies obtained predominantly transplacentally before attaining the suggested age of administering the measles vaccine. The occurrence of other symptoms like cough, conjunctivitis, and coryza undermines the immune system of the infant, consequently resulting in other serious complications like pneumonia, diarrhea, SSPE, or even death. Measures to prevent the measles prevalence and mortality rate in infants comprise supporting care, Vitamin A supplementation, timely vaccines for the non-infected babies, confining suspected cases, and sustaining stringent public health surveillance in place all the time to detect and proactively treat any suspected case of measles.